nivolumab + tegafur-gimeracil-oteracil potassium

Nivolumab + tegafur-gimeracil-oteracil potassium is a **combination therapy** used in the treatment of gastric and gastroesophageal junction cancers. **Nivolumab** is a human monoclonal antibody targeting programmed cell death protein-1 (**PD-1**), functioning as an immune checkpoint inhibitor. **Tegafur-gimeracil-oteracil potassium (S-1)** is an oral fluoropyrimidine prodrug combination that interferes with DNA synthesis and repair by inhibiting thymidylate synthase. The combination exploits both direct cytotoxic chemotherapy and immune-mediated antitumor effects. This combination has primarily been studied as an adjuvant or first-line therapy, including in phase II and III trials such as ATTRACTION-4 and ATTRACTION-5, mainly in East Asian populations. The primary clinical indications under investigation are **gastric cancer** and **esophagogastric junction cancer**, particularly in HER2-negative, advanced, unresectable, or postoperative settings[2][3][5][1][4].

Other names

nivolumab + S-1nivolumab + tegafur/gimeracil/oteracil potassiumnivolumab + SOXnivolumab + S-1 therapy